Advertisement
IDYA vs VRTX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and VRTX is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IDYA’s FA Score shows that 0 FA rating(s) are green whileVRTX’s FA Score has 0 green FA rating(s).
- IDYA’s FA Score: 0 green, 5 red.
- VRTX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IDYA’s TA Score shows that 5 TA indicator(s) are bullish while VRTX’s TA Score has 3 bullish TA indicator(s).
- IDYA’s TA Score: 5 bullish, 4 bearish.
- VRTX’s TA Score: 3 bullish, 5 bearish.
Price Growth
IDYA (@Biotechnology) experienced а +10.63% price change this week, while VRTX (@Biotechnology) price change was +1.30% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.
Reported Earning Dates
IDYA is expected to report earnings on Nov 11, 2025.
VRTX is expected to report earnings on Oct 29, 2025.
Industries' Descriptions
@Biotechnology (+2.52% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| IDYA | VRTX | IDYA / VRTX | |
| Capitalization | 2.38B | 102B | 2% |
| EBITDA | -380.2M | 4.59B | -8% |
| Gain YTD | 5.681 | -1.634 | -348% |
| P/E Ratio | N/A | 28.17 | - |
| Revenue | 7M | 11.4B | 0% |
| Total Cash | 670M | 6.38B | 10% |
| Total Debt | 26.6M | 1.53B | 2% |
IDYA | VRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 68 | 50 | |
SMR RATING 1..100 | 96 | 41 | |
PRICE GROWTH RATING 1..100 | 47 | 62 | |
P/E GROWTH RATING 1..100 | 100 | 42 | |
SEASONALITY SCORE 1..100 | 50 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IDYA's Valuation (63) in the null industry is in the same range as VRTX (72) in the Biotechnology industry. This means that IDYA’s stock grew similarly to VRTX’s over the last 12 months.
VRTX's Profit vs Risk Rating (50) in the Biotechnology industry is in the same range as IDYA (68) in the null industry. This means that VRTX’s stock grew similarly to IDYA’s over the last 12 months.
VRTX's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for IDYA (96) in the null industry. This means that VRTX’s stock grew somewhat faster than IDYA’s over the last 12 months.
IDYA's Price Growth Rating (47) in the null industry is in the same range as VRTX (62) in the Biotechnology industry. This means that IDYA’s stock grew similarly to VRTX’s over the last 12 months.
VRTX's P/E Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for IDYA (100) in the null industry. This means that VRTX’s stock grew somewhat faster than IDYA’s over the last 12 months.
| IDYA | VRTX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 74% | 1 day ago 83% |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 56% |
| Momentum ODDS (%) | 1 day ago 79% | 1 day ago 49% |
| MACD ODDS (%) | 1 day ago 84% | 1 day ago 63% |
| TrendWeek ODDS (%) | 1 day ago 77% | 1 day ago 58% |
| TrendMonth ODDS (%) | 1 day ago 81% | 1 day ago 62% |
| Advances ODDS (%) | 1 day ago 77% | 10 days ago 59% |
| Declines ODDS (%) | 9 days ago 77% | 12 days ago 41% |
| BollingerBands ODDS (%) | 1 day ago 76% | 1 day ago 48% |
| Aroon ODDS (%) | 1 day ago 81% | 1 day ago 38% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AOK | 39.72 | 0.10 | +0.25% |
| iShares Core 30/70 Cnsrv Allc ETF | |||
| NOCT | 56.21 | 0.06 | +0.10% |
| Innovator Growth-100 Pwr Buff ETF™ Oct | |||
| BBSB | 99.08 | N/A | N/A |
| JPMorgan BetaBuilders U.S. TrsBd1-3YrETF | |||
| SEPP | 29.46 | -0.03 | -0.11% |
| PGIM S&P 500 Buffer 12 ETF - Sep | |||
| INDA | 52.48 | -0.11 | -0.21% |
| iShares MSCI India ETF | |||